Safety and effectiveness of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome: final results from a post-marketing surveillance in Japan
Modern Rheumatology · 2026
DOI: 10.1093/mr/roaf104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2026. Verfasst von Chihiro Kato und 2 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma K.K., Tokyo, Japan. Hauptthemen laut MEDLINE: Cryopyrin-Associated Periodic Syndromes, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma AG, Basel, Switzerland.
Abstract (Originalsprache)
Objectives
To assess the real-world safety and effectiveness of canakinumab, a monoclonal anti-interleukin-1β antibody, in patients with cryopyrin-associated periodic syndrome (CAPS) in a real-world setting in Japan.
Methods
All patients with CAPS who received canakinumab treatment after drug approval in Japan were registered in a post-marketing all-patient surveillance with 2-year observation period and a follow-up period of up to 5 years.
Results
Of 93 patients in the safety analysis set, the proportion of patients with any adverse drug reactions (ADRs) and any serious ADRs was 33.33% and 4.30%, respectively. The most common ADRs were infections and infestations (21.51%). Of 70 new and 18 continuing patients (roll-over from a previous clinical trial) in the effectiveness analysis set, the proportion of responders among new and continuing patients, who achieved both clinical and serological remissions, was 78.57% and 83.33%, respectively, at Week 24. Most responders remained without relapse after the remission until Week 104 (98.11% of new and 100% of continuing patients). Clinical symptoms related to auditory, joint, visual, renal, and central nervous system maintained or improved in the majority of patients.
Conclusions
Canakinumab was well-tolerated and effective during long-term treatment for patients with CAPS in the real-world setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novartis Pharma K.K., Tokyo, Japan.
- Department of Pediatrics and Child Health, Kurume University School of Medicine, Fukuoka, Japan.
ORCID-Profile: Ryuta Nishikomori
Förderung
- Novartis Pharma AG, Basel, Switzerland
Zitieren
APA
Kato, C., Sasajima, T., & Nishikomori, R. (2026). Safety and effectiveness of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome: final results from a post-marketing surveillance in Japan. Modern Rheumatology. https://doi.org/10.1093/mr/roaf104
Vancouver
Kato C, Sasajima T, Nishikomori R. Safety and effectiveness of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome: final results from a post-marketing surveillance in Japan. Modern Rheumatology. 2026. doi:10.1093/mr/roaf104
BibTeX
@article{Kato2026,
author = {Kato, Chihiro and Sasajima, Takayoshi and Nishikomori, Ryuta},
title = {Safety and effectiveness of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome: final results from a post-marketing surveillance in Japan},
journal = {Modern Rheumatology},
year = {2026},
doi = {10.1093/mr/roaf104}
}
EUVIMED